Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI0101 (NXC-201) CART in Multiple Myeloma and Light-Chain Amyloidosis
NCT06971380Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NXC-201 in multiple myeloma (MM) and light-chain amyloidosis. Primary endpoint: Clinical response to HBI0101 CART at 24 months. Started Mar 2025; status: recruiting.
02
Drugs
NXC-201
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT06971380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971380.